Infections caused by carbapenem-resistant Acinetobacter spp. are considered an urgent public health problem. Antibiotic options are scarce but new drugs may be available in the near future. We discuss this important topic with experts in the field.
- Acinetobacter as an opportunistic pathogen.
- Therapeutic approaches for Acinetobacter infections.
- The future approach for this MDR organisms.
- Dr. Yohei Doi, Professor and Director, Center for Innovative Antimicrobial Therapy, University of Pittsburgh Medical Center, Pittsburgh, Pa.
- Dr. Joseph Patrick Hornak. Fellow, Infectious Diseases, University of Texas Medical Branch, Galveston, Texas.
Visit journals.asm.org/journal/aac to browse issues and/or submit a manuscript.
Subscribe to Editors in Conversation (free) on Apple Podcasts, Google Podcasts, Android, Spotify or by email.